Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $930000.0.

  • Celldex Therapeutics' Other Accumulated Expenses fell 3338.11% to $930000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $930000.0, marking a year-over-year decrease of 3338.11%. This contributed to the annual value of $942000.0 for FY2024, which is 7637.91% down from last year.
  • As of Q3 2025, Celldex Therapeutics' Other Accumulated Expenses stood at $930000.0, which was down 3338.11% from $930000.0 recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' Other Accumulated Expenses registered a high of $7.6 million during Q1 2021, and its lowest value of $930000.0 during Q2 2025.
  • Its 5-year average for Other Accumulated Expenses is $2.4 million, with a median of $1.6 million in 2021.
  • Per our database at Business Quant, Celldex Therapeutics' Other Accumulated Expenses skyrocketed by 30282.83% in 2023 and then tumbled by 7637.91% in 2024.
  • Over the past 5 years, Celldex Therapeutics' Other Accumulated Expenses (Quarter) stood at $1.6 million in 2021, then crashed by 36.29% to $990000.0 in 2022, then surged by 302.83% to $4.0 million in 2023, then plummeted by 76.38% to $942000.0 in 2024, then dropped by 1.27% to $930000.0 in 2025.
  • Its Other Accumulated Expenses was $930000.0 in Q3 2025, compared to $930000.0 in Q2 2025 and $1.7 million in Q1 2025.